Last reviewed · How we verify
Triptorlin or Leuprorelin
Triptorlin or Leuprorelin is a Small molecule drug developed by Ruijin Hospital. It is currently FDA-approved. Also known as: Triptorlin, Leuprorelin.
Triptorlin or Leuprorelin is a protein-based medication used to treat Central Precocious Puberty. It is a synthetic analogue of gonadotropin-releasing hormone (GnRH) that works by inhibiting the production of sex hormones.
At a glance
| Generic name | Triptorlin or Leuprorelin |
|---|---|
| Also known as | Triptorlin, Leuprorelin |
| Sponsor | Ruijin Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triptorlin or Leuprorelin CI brief — competitive landscape report
- Triptorlin or Leuprorelin updates RSS · CI watch RSS
- Ruijin Hospital portfolio CI
Frequently asked questions about Triptorlin or Leuprorelin
What is Triptorlin or Leuprorelin?
Who makes Triptorlin or Leuprorelin?
Is Triptorlin or Leuprorelin also known as anything else?
What development phase is Triptorlin or Leuprorelin in?
Related
- Manufacturer: Ruijin Hospital — full pipeline
- Also known as: Triptorlin, Leuprorelin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing